prolyl-prolyl-glycine: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 152199 |
| CHEMBL ID | 288208 |
| CHEBI ID | 162592 |
| SCHEMBL ID | 3359412 |
| MeSH ID | M0130054 |
| Synonym |
|---|
| CHEMBL288208 |
| CHEBI:162592 |
| 16875-10-8 |
| 2-[[(2s)-1-[(2s)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetic acid |
| pro-pro-gly |
| glycine, n-(1-l-prolyl-l-prolyl)- |
| prolyl-prolyl-glycine |
| l-prolyl-l-prolyl-glycine |
| SCHEMBL3359412 |
| DTXSID30168607 |
| 2-((s)-1-((s)-pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetic acid |
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID18274 | Km by incubating with prolyl-4-hydroxylase under standard assay conditions | 2000 | Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14 | Mechanistic studies on prolyl-4-hydroxylase: the vitamin C requiring uncoupled oxidation. |
| AID22790 | Percent Vmax by incubating with prolyl-4-hydroxylase under standard assay conditions | 2000 | Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14 | Mechanistic studies on prolyl-4-hydroxylase: the vitamin C requiring uncoupled oxidation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||